The National Cancer Institute will cease funding the 26-year-old Pediatric Brain Tumor Consortium, redirecting resources towards the broader Children's Oncology Group Pediatric Early Phase Clinical Trials Network. This strategic pivot reflects evolving priorities in pediatric oncology research, though collaborations will ensure ongoing trials transition smoothly. The change aims to unify efforts in advancing childhood cancer therapeutics amid uncertain NIH funding landscapes.